NCT04569032 2026-02-18
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Phase 2 Completed
Seagen Inc.
Dana-Farber Cancer Institute
Henan Cancer Hospital
Eastern Cooperative Oncology Group
Second Affiliated Hospital, School of Medicine, Zhejiang University
Czech Lymphoma Study Group
University of California, San Francisco
Eisai Inc.
Lymphoma Study Association
Yale University